Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $50.00 at HC Wainwright

Key Points

• HC Wainwright raised the price target for Maze Therapeutics from $34.00 to $50.00, suggesting a potential upside of 101.61% from its current price and maintaining a "buy" rating on the stock.
• Other analysts, such as BTIG Research and Wall Street Zen, have also issued positive ratings; the consensus rating for Maze Therapeutics is currently a "Buy" with an average price target of $30.17.
• Maze Therapeutics recently reported its quarterly earnings, exceeding expectations with an EPS of ($0.77), slightly higher than the consensus estimate of ($0.79).

Maze Therapeutics (NASDAQ:MAZE - Free Report) had its price target raised by HC Wainwright from $34.00 to $50.00 in a report released on Friday, Marketbeat.com reports. They currently have a buy rating on the stock.

Several other equities analysts also recently weighed in on the company. BTIG Research lifted their target price on Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Wedbush assumed coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price objective on the stock. Finally, Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $32.67.

Maze Therapeutics Stock Performance

Shares of MAZE traded up $0.57 during trading hours on Friday, hitting $24.03. The stock had a trading volume of 129,839 shares, compared to its average volume of 262,638. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $25.50. The stock has a fifty day moving average price of $15.67 and a 200 day moving average price of $12.43.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Insider Activity at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the business's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a filing with the SEC, which is available through this link.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund bought a new stake in shares of Maze Therapeutics during the first quarter worth $25,000. CWM LLC purchased a new position in shares of Maze Therapeutics in the 2nd quarter valued at $28,000. Corebridge Financial Inc. purchased a new position in shares of Maze Therapeutics in the 1st quarter valued at $48,000. Legal & General Group Plc lifted its holdings in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock valued at $52,000 after purchasing an additional 3,371 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Maze Therapeutics by 452.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock valued at $57,000 after purchasing an additional 3,774 shares during the last quarter.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.